fbpx

Weekly Top News – IBD – October 7, 2019

October 7, 2019

Stelara (ustekinumab) / J&J
REAL WORLD EXPERIENCE WITH USTEKINUMAB IN PAEDIATRIC CROHN´S DISEASE. A MULTICENTRE RETROSPECTIVE STUDY FROM PAEDIATRIC IBD PORTO GROUP OF ESPGHAN (UEGW 2019) – Oct 4, 2019 – Abstract #LB05; Pres time: Oct 21, 2019; 02:48 PM – 03:00 PM; Location: F3; “This abstract will be published on October 21, 2019”

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi launch estimate: 2022 for Crohn’s disease and 2023 for ulcerative colitis (UBS) – Oct 2, 2019 – A subscription to Thomson ONE is required to gain full access to report 68017232; Page no: 1; REPORT TITLE: “US Pharmaceuticals “Gastroenterology – Takeaways from UBS expert symposium””; AUTHOR: Jacob, Navin, et al; DATE: 09/26/2019

 

Humira (adalimumab) / Eisai, AbbVie
An open-label randomized trial COmparing staNdard of care versus Treat to target with telemonitoRing and patient education in patients with ulcerative cOlitis initiating adalimumab : The CONTROL trial (clinicaltrialsregister.eu) – Oct 5, 2019 – P4; N=238; Ongoing; Sponsor: GETAID

 

Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer; Remsima SC (infliximab biosimilar SC) / Celltrion
NONINFERIORITY OF NOVEL SUBCUTANEOUS INFLIXIMAB (CT-P13) TO INTRAVENOUS INFLIXIMAB (CT-P13) IN PATIENTS WITH ACTIVE CROHN’S DISEASE AND ULCERATIVE COLITIS: WEEK 30 RESULTS FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL (UEGW 2019) – Oct 4, 2019 – Abstract #LB02; Pres time: Oct 21, 2019; 02:12 PM – 02:24 PM; Location: F3; “This abstract will be published on October 21, 2019”

 

Entyvio (vedolizumab) / Takeda
Entyvio sales projection: $4.3B by 2022 (Deutsche Bank Research) – Oct 1, 2019 – A subscription to Thomson ONE is required to gain full access to report 67968779; Page no: 2; REPORT TITLE: “Roche: Pharma day; biosimilar headwinds should soon be in the rear view”; AUTHOR: Parkes, Richard, et al; DATE: 09/17/2019

 

Rinvoq (upadacitinib) / AbbVie
Rinvoq sales projection: $5.6B peak (UBS) – Oct 5, 2019 – A subscription to Thomson ONE is required to gain full access to report 68016563; Page no: 1; REPORT TITLE: “US Pharmaceuticals “UBS healthcare expert symposium: Dermatology panel key …”; AUTHOR: Jacob, Navin, et al; DATE: 09/26/2019

 

etrolizumab (RG7413) / Roche
Etrolizumab sales projection: CHF765M in 2025 (Deutsche Bank Research) – Oct 4, 2019 – A subscription to Thomson ONE is required to gain full access to report 67968779; Page no: 2; REPORT TITLE: “Roche Holding Ltd- Roche: Pharma Day; Biosimilar headwinds should soon be in the rear view”; AUTHOR: Parkes, Richard, et al; DATE: 09/17/2019
Sales projection

Otezla (apremilast) / Amgen
Otezla sales projection: $1.9B in 2019 and $2.2B in 2020 (Cowen & Co) – Sep 30, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 2914; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

BMS-986165 / BMS
BMS-986165 sales projection: Consensus of $3.5B peak (Exane BNP Paribas) – Oct 4, 2019 – A subscription to Thomson ONE is required to gain full access to report 67972680; Page no: 38; REPORT TITLE: “Pharmaceuticals: Champions League 2019: Powered by pulse “; AUTHOR: Hector, Luisa, et al; DATE: 09/17/2019

 

Xeljanz (tofacitinib) / Pfizer
Xeljanz sales projection: $1B peak for gastrointestinal disorders (UBS) – Oct 2, 2019 – A subscription to Thomson ONE is required to gain full access to report 68017232; Page no: 1; REPORT TITLE: “US Pharmaceuticals “Gastroenterology – Takeaways from UBS expert symposium””; AUTHOR: Jacob, Navin, et al; DATE: 09/26/2019

No Comments

Post a Comment

Comment
Name
Email
Website